This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hirschfeld, S. Articles by Pazdur, R. Search for Related Content PubMed PubMed Citation Articles by Hirschfeld, S. Articles by Pazdur, R.

Pediatric Oncology: Regulatory Initiatives

Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, USA

Correspondence: Steven Hirschfeld, M.D., Ph.D., Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, WOC-II, 1451 Rockville Pike, Rockville, Maryland 20852, USA. Telephone: 301-827-1532; Fax: 301-594-0499; e-mail: hirschfelds{at}cder.fda.gov

The majority of children with cancer receive therapy as participants in clinical research protocols coordinated by national pediatric cooperative groups. One of the highest priorities of these groups is the development of novel therapies. Due to differences in the biology of pediatric and adult tumors and in physiology between adults and children, it is usually necessary to evaluate the safety and effectiveness of new drugs separately in adult and pediatric populations. To stimulate the development of new therapies for pediatric indications and encourage the submission of clinical data to support pediatric product labeling, the U.S. Food and Drug Administration has undertaken two initiatives. In 1998 the FDA issued a regulation (The 1998 Final Pediatric Rule) that mandated if a drug or biological is under review for a claim and the disease exists in both pediatric and adult populations, pediatric studies must be performed. Section 111 of the FDA Modernization Act of 1997 states that if a drug product has exclusivity based on a patent or marketing license, the exclusivity can be extended by six months for the submission of pediatric data to the FDA. The incentive applies to both approved drugs and those under development. These initiatives are intended to enhance access to new anticancer therapies and promote labeling for pediatric oncology indications.

Key Words. Pediatric • FDA regulations • Protocols • Pediatric oncology

This article has been cited by other articles:

				H. Mellstedt, D. Niederwieser, and H. Ludwig The challenge of biosimilars Ann. Onc., March 1, 2008; 19(3): 411 - 419. [Abstract] [Full Text] [PDF]

				M. L. Eder, A. D. Yamokoski, P. W. Wittmann, and E. D. Kodish Improving Informed Consent: Suggestions From Parents of Children With Leukemia Pediatrics, April 1, 2007; 119(4): e849 - e859. [Abstract] [Full Text] [PDF]

				S. Hirschfeld, P. T.C. Ho, M. Smith, and R. Pazdur Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives J. Clin. Oncol., March 15, 2003; 21(6): 1066 - 1073. [Abstract] [Full Text] [PDF]